Mental Health Clinics in Dobbs Ferry, NY Accepting Medicare
6 Mental Health Clinics found. Showing 1 - 6
 Natalie Schreter Lcsw Plplc Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 145 Palisade St Ste 216, Dobbs Ferry, NY 10522 Phone: 310-467-5440 |
Marc S. Kleber, Ph.d., Psychologist, P.c. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 369 Ashford Ave, 1b, Dobbs Ferry, NY 10522 Phone: 914-231-6878 |
Linda Sadler, Psy.d., Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 145 Palisade St Ste 396, Dobbs Ferry, NY 10522 Phone: 914-384-3333 |
Westchester Center For Cognitive Assessment Llc Clinical Neuropsychologist Medicare: Medicare Enrolled Practice Location: 89 Mohican Pk Ave, Dobbs Ferry, NY 10522 Phone: 914-355-8904 |
Innovative Spectrum Services Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 145 Palisade St Ste 200, Dobbs Ferry, NY 10522 Phone: 914-214-4404 |
Dr. Kristin Perry, Psychologist, P.c. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 40 Beechdale Rd, Dobbs Ferry, NY 10522 Phone: 914-591-1115 |
News Archive
ALMA receives ExxonMobil $250,000 grant to combat malaria
The African Leaders Malaria Alliance, an alliance of 39 African leaders, announced today that it has been awarded a $250,000 grant from the ExxonMobil Foundation to help with its campaign to combat malaria.
Obesity keeps out recruits, raising medical costs for military
The Fiscal Times reports that the U.S. military every year discharges more than 1,200 enlistees before their contracts are over because of weight problems. "The cost of recruiting and training all their replacements? A hefty $50,000 per person — or roughly $60 million a year." A nonprofit group of senior military leaders recently released a report that claimed weight problems are the leading medical reason recruits are rejected for service in the military.
Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint
Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.
Special issue provides comprehensive overview of latest findings in the area of skeletal research
While there is good understanding of how bone mass, and more recently bone architecture, affects fracture risk, far less is known about the material properties of bone, or how these can impart resilience or fragility to the skeleton.
Amgen granted FDA priority review designation for denosumab BLA
Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.
› Verified 2 days ago